ID: ALA4462073

Max Phase: Preclinical

Molecular Formula: C17H15F3N4O

Molecular Weight: 348.33

Molecule Type: Unknown

Representations

Canonical SMILES:  CN(C)C(=O)Cn1ccc2ncc(-c3cccc(C(F)(F)F)n3)cc21

Standard InChI:  InChI=1S/C17H15F3N4O/c1-23(2)16(25)10-24-7-6-13-14(24)8-11(9-21-13)12-4-3-5-15(22-12)17(18,19)20/h3-9H,10H2,1-2H3

Standard InChI Key:  MNKQUDROCZIINF-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 348.33

Molecular Weight (Monoisotopic): 348.1198

AlogP: 3.21

#Rotatable Bonds: 3

Polar Surface Area: 51.02

Molecular Species: NEUTRAL

HBA: 4

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 3.92

CX LogP: 2.66

CX LogD: 2.66

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.73

Np Likeness Score: -1.91

References

1. Chrovian CC, Soyode-Johnson A, Wall JL, Rech JC, Schoellerman J, Lord B, Coe KJ, Carruthers NI, Nguyen L, Jiang X, Koudriakova T, Balana B, Letavic MA..  (2019)  1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.,  10  (3): [PMID:30891123] [10.1021/acsmedchemlett.8b00542]

Source

Source(1):

• Scientific Literature